Genera Biosystems hits ASX to boost Dx tech
This article was originally published in Clinica
Executive Summary
Molecular diagnostics specialist Genera Biosystems has floated on the Australian Securities Exchange (ASX) with shares opening on the market at Aus$0.40 ($0.37) per share. The Bundoora, Victoria-based company is currently developing its PapType test, which is designed to help pathology laboratories to identify human papillomavirus (HPV) in cervical smear samples. Genera is also working on a test for sexually transmitted diseases which is in the pre-clinical development stage. The firm’s chairman Fernando Careri said that the proceeds from the flotation on the ASX will help it progress towards full commercialisation of its tests over the next two years. Shares were marginally up at Aus$0.45 on the first day of trading (June 11).